Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT study of AZD3293
NCT02040987Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lanabecestat in Alzheimer's disease (AD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Change in time-matched QTcF intervals up to 69 days. Started Jan 2014; status: completed.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02040987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040987.